A prospective study of cytomegalovirus reactivation in hematological patients treated with bendamustine

A prospective study of cytomegalovirus reactivation in hematological patients treated with bendamustine - BendaCMV study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015734

Enrollment

Registered

2014-11-21

Start date

2014-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who gave written informed consent abotu this study

Exclusion criteria

Exclusion criteria: 1.active infection 2.primary immunodeficiency, 3.AIDS 4.past history of hematopoietic transplantation 5.female patients who are breast feeding or pregnant. 6.Uncontrollable psychiatric illness 7.past history of reactivation of cytomegalovirus 8.CMV IgG negative patients 9.patients who, in the judgment of the investigator, would be inappropriate for entry into this study

Design outcomes

Primary

Measure	Time frame
Analysis of reactivation of cytomegalovirus in patients treated with bendamustine	—

Secondary

Measure	Time frame
Analysis of CMV specific T lymphocytes Analysis of the effect of immunosuppression after bendamustine Analysis of side effect induced by antiviral drug	—

Countries

Japan

Contacts

Public ContactUgai Tomotaka

Saitama Medical Center, Jichi Medical University Division of Hematology

harukakanata58@yahoo.co.jp048-647-2111

Outcome results